Skip to main content

Asciminib

Details of the Drug
Generic Name:
Asciminib
Drug Type:
Kinase inhibitor (STAMP [Specifically Targeting the ABL Myristoyl Pocket] inhibitor)
How the Drug is Given:

By mouth

Names:
Scemblix®
Asciminib

Indications and Usage

Asciminib is indicated for the treatment of adult patients with: 

  • Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). 
    This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
  • Previously treated Ph+ CML in CP.
  • Ph+ CML in CP with the T315I mutation. 

Side effects needing medical attention

Most common adverse reactions are upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.